Oral absorption of diflomotecan, a new E-ring modified camptothecin analogue, administered as soft-gel capsule.

2045 Background: The E-ring modified camptothecin analogue diflomotecan (BN80915, Ipsen Group) is a new topoisomerase I inhibitor. Its clinical development includes five phase I studies using the iv and oral routes of administration. The trial reported here is in progress to explore the safety, PK and PK/PD haematotoxicity correlation of diflomotecan… CONTINUE READING